Company
Headquarters: Saluggia, VC, Italy
Employees: 2,024
CEO: Mr. Carlo Rosa
€5.30 Billion
EUR as of July 1, 2024
US$5.69 Billion
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $204.45 B |
| Danaher | $177.21 B |
| Siemens Healthineers AG | $63.84 B |
| DexCom, Inc. | $45.21 B |
| Lonza Group Ltd | $39.85 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostic and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. It provides various immunodiagnostic platforms, including LIAISON, LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform, comprising of LIAISON MDX. DiaSorin S.p.A. has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of Point-of-Care molecular platform; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
DiaSorin S.p.A. has the following listings and related stock indices.
Stock: MTA: DIA wb_incandescent
Stock: FSX: 34D wb_incandescent
Stock: OTC: DSRLF wb_incandescent